Research Reports from Harvard Medical School Provide New Insights into Follicular Lymphoma (Advancements in the Management of Follicular Lymphoma: A Comprehensive Review).
In: Cancer Gene Therapy Week, 2024-06-20, S. 75-75
serialPeriodical
Zugriff:
A research report from Harvard Medical School provides new insights into follicular lymphoma, the most common subtype of indolent non-Hodgkin lymphoma in Western countries. While follicular lymphoma is generally incurable, standard initial therapies have high response rates and durable remissions for most patients. The report discusses the initial staging, prognosis, and treatment options for newly diagnosed and relapsed/refractory follicular lymphoma, including active surveillance, radiotherapy, rituximab monotherapy, chemoimmunotherapy, and targeted agents and immunotherapies. The study also highlights the potential of CAR-T cell therapy and CD3/CD20 bispecific antibodies in changing treatment algorithms for follicular lymphoma. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Research Reports from Harvard Medical School Provide New Insights into Follicular Lymphoma (Advancements in the Management of Follicular Lymphoma: A Comprehensive Review).
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2024-06-20, S. 75-75 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|